Latest Studies and Clinical Trials Lead to Compelling Developments Indicating Cannabinoids May Contain Significant Analgesic Effects in Treating Various Diseases & Conditions

CORAL SPRINGS, Florida, December 16, 2015 /PRNewswire/ --

Comprehensive studies and research efforts are lending support that medical marijuana & cannabinoids may be safe, demonstrate a modest analgesic effect and could provide a reasonable treatment option for treatment chronic non-cancer pain and other ailments & diseases. Today's leading companies with recent developments of interest are Cannabis Science, Inc. (OTC: CBIS), Compass Diversified Holdings (NYSE: CODI), NEMUS Bioscience, Inc. (OTC: NMUS), GW Pharmaceuticals (NASDAQ: GWPH) and Insys Therapeutics, Inc. (NASDAQ: INSY)

Cannabis Science, Inc. (OTC: CBIS), a U.S. company specializing in the development of cannabis-based medicines, announced that it has entered into a comprehensive clinical drug development to focus on delivering GMP quality pre-clinical data to enable entry of CS-NEURO-1 into a Phase I human study in Europe with ImmunoClin (OTC: IMCL). After ImmunoClin successfully completed its one-year formulation work for CBIS, focusing on cannabis extracts and cannabinoids, the results are compelling and conclusive. ImmunoClin will, under its class I license, initiate, manage, and coordinate all aspects of the new comprehensive clinical research program on behalf of Cannabis Science. The new program will focus on delivering compliant GMP quality pre-clinical data, including cultivation of CBIS specific cannabis strains, formulation and manufacturing of clinical grade material to enable entry of CS-NEURO-1 and other cannabinoid based products into a Phase I human studies in Europe.

Read the full Cannabis Science (CBIS) Press Release & Bonus Coverage at:  http://www.financialnewsmedia.com/profiles/cbis.html

Additional Cannabis Science coverage issued by TomorrowsBlueChips.com: As the door begins to close on 2015, investors seeking to build a strong foundation for 2016 will want to take a glance back at the most relevant industries heading into the new year, and to make moves accordingly. Small cap biostocks in particular made strides over the last couple of financial quarters, with Cannabis Science, Inc. (CBIS) standing out in recent weeks with several key distribution and development moves. On Tuesday, Cannabis Science announced that it has entered into partnership with ImmunoClin (IMCL) to oversee all aspects of a new clinical research program for Cannabis Science. The intent with this program will be to place an emphasis on GMP quality pre-clinical data, a process that will include cultivation, formulation, and manufacturing of various strains of clinical grade cannibinoid products.

In addition to the innovation of this new program, Cannabis Bioscience has been busy diversifying its partnerships and business intent. Last week, the company entered a new, high-dosage product line of its CBD, Sativa, and Indica product capsules into an industry-leading event called Emerald Cup in Santa Rosa, California. The event should enhance exposure to Cannabis Bioscience's product line by way of sampling, vender booths, presentations, and even various contests featuring cannabin products. But Cannabis Bioscience, while focusing on the endeavor of clinical research and the diversification of its product capsule distribution, has also been at work on a line of Animal Care products released through the company's recently acquired, wholly-owned subsidiary, Equi-Pharm LLC. Thanks to this move and others, such as Cannabis Bioscience's retention of I-Business Management for the purposes of investor and public relations as well as corporate and product branding, industry analysts have begun to raise projections for the company's stock.  SOURCE: Seraphim Strategies LLC

In other sector related news and happenings:  Compass Diversified Holdings (NYSE: CODI), an owner of leading middle market businesses, announced after the close on Tuesday that its subsidiary, Fresh Hemp Foods Ltd. ("Manitoba Harvest"), has acquired Hemp Oil Canada, Inc. ("HOCI") for a purchase price of C$42 million, not including working capital and certain other adjustments.

NEMUS Bioscience, Inc. (OTCQB: NMUS) has announced the in-licensing of derivative formulations of the cannabinoid molecule, cannabidiol (CBD). CBD is differentiated from tetrahydrocannabidiol (THC) in that it is a non-psychogenic cannabinoid with multiple associated activities in mammalian systems, including but not limited to, immune regulation, anti-inflammatory and anti-cancer activity, neuro-modulation and neuroprotective qualities. The in-licensing includes not only formulation derivatives of the CBD molecule but also multiple routes of administration and methods of use.

From a recent article published by Fool.com:  Ahead of data from trials evaluating its marijuana-derived therapies for the treatment of epilepsy, shares in GW Pharmaceuticals (NASDAQ:GWPH) increased by 10.5% in November. Perhaps no other company is as focused on using marijuana to develop medicine as GW Pharmaceuticals. The company already has one THC drug, Sativex, on the European market as a treatment for multiple sclerosis muscle spasms. GW's marijuana studies include the evaluation of the marijuana cannabidiol CBD for the treatment of Dravet syndrome and Lennox-Gastaut syndrome, two rare forms of epilepsy. GW Pharmaceuticals is expected to release data from ongoing late-stage trials in these indications in Q1. If those results are positive, then its drug, Epidiolex, may offer newfound hope to thousands of patients; earlier this year, the company reported that patients participating in a non-placebo controlled study experienced 52% fewer seizures when taking Epidiolex for 12 weeks... ...However, even if Epidiolex has positive efficacy in its trials, there's no guarantee that GW Pharmaceuticals will be able to outpace competitors like Insys Therapeutics (NASDAQ:INSY) or win away share from medical marijuana dispensaries that are already providing high-dose-CBD marijuana varieties to epilepsy patients.  Insys Therapeutics is conducting its own studies of CBD in Dravet syndrome and Lennox-Gastaut syndrome, and it also expects to report results soon. If Insys Therapeutics' results match or beat GW Pharmaceuticals' results, there's no telling how the competitive landscape will shape up.  Read the full article on the Fool.com - Source: http://www.fool.com/investing/general/2015/12/06/why-medical-marijuana-caused-gw-pharmaceuticals-to.aspx?source=eogyholnk0000001&utm_source=yahoo&utm_medium=feed&utm_campaign=article  

FinancialNewsMedia.com is leading provider of third party publishing & news dissemination services.  If you would like more information regarding our news coverage solutions, please visit http://www.financialnewsmedia.com for more details.  Get an edge on the market with our Premium News Alerts that are FREE for a limited time at financialnewsmedia.com.  Follow us on Facebook: facebook.com/financialnewsmedia and Twitter:  twitter.com/FNMgroup. 

DISCLAIMER:  FN Media Group LLC (FNMG) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels.  FNMG is NOT affiliated in any manner with any company mentioned herein.  FNMG and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security.  FNMG's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities.  The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material.  All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks.  All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release.  FNMG is not liable for any investment decisions by its readers or subscribers.  Investors are cautioned that they may lose all or a portion of their investment when investing in stocks.  For current services performed FNMG has been compensated one thousand two hundred dollars for news coverage of Cannabis Science, Inc. by a non-affiliated third party.  FNMG HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements.

Contact Information:
Company:  FN Media Group, LLC
Contact email:  [email protected]
U.S. Phone:  +1-954-345-0611
URL: http://www.financialnewsmedia.com

SOURCE FN Media Group LLC